Premium
Hydroxyprogesterone caproate therapy in advanced endometrial cancer
Author(s) -
Reifenstein Edward C.
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197103)27:3<485::aid-cncr2820270302>3.0.co;2-1
Subject(s) - medicine , hydroxyprogesterone , endometrial cancer , concomitant , incidence (geometry) , cancer , gynecology , adenocarcinoma , metastasis , gastroenterology , urology , hormone , steroid , physics , optics
In 314 women with advanced progressing adenocarcinoma of the uterine corpus (endometrial cancer) no longer responding to established anticancer measures, hydroxyprogesterone caproate Hydroxyprogesterone caproate, 17‐alpha‐hydroxy‐progesterone‐n‐caproate; Delalutin, E. R. Squibb and Sons, Inc., New York, N.Y. (1.0 or more g/week intramuscularly for 4 or more weeks) induced an objective response (averaging 20 months in duration) consisting of regression in 30.2% or arrest of the disease in 6.8%. These responders survived an average of 27 months, four times as long as the nonresponders. The incidence of responders was significantly greater in patients with slowly growing tumors and in those treated for 12 or more weeks. Neither the objective response rate nor the duration of survival was influenced significantly by the age of the patient, the amount of hydroxyprogesterone caproate per week, the site of neoplastic metastasis or recurrence, the type of previous anticancer therapy, or presence of concomitant established anticancer therapy. Hydroxyprogesterone caproate (up to 7.0 g/week) was safe and well tolerated; undesirable manifestations occurred infrequently.